Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Long-Term Extension (LTE) Study With Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599) in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus Who Have Completed the M19-130 Phase 2 Randomized Controlled Trial (RCT)

NCT04451772 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT04451772
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04451772 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Long-Term Extension (LTE) Study With Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599) in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus Who Have Completed the M19-130 Phase 2 Randomized Controlled Trial (RCT)
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Completed
Start date
July 27, 2020
Completion date
January 3, 2024
Enrollment
185 (actual)
Sites
87

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus (sle)